Kinase inhibitors for advanced medullary thyroid carcinoma.

Item

http://www.wikidata.org/entity/Q35895485

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Kinase inhibitors for advanced medullary thyroid carcinoma.

@ast

Kinase inhibitors for advanced medullary thyroid carcinoma.

@en

type

Item

label

Kinase inhibitors for advanced medullary thyroid carcinoma.

@ast

Kinase inhibitors for advanced medullary thyroid carcinoma.

@en

prefLabel

Kinase inhibitors for advanced medullary thyroid carcinoma.

@ast

Kinase inhibitors for advanced medullary thyroid carcinoma.

@en

P1476

Kinase inhibitors for advanced medullary thyroid carcinoma.

@en

P2093

Camila L Nascimento

http://www.w3.org/2001/XMLSchema#string

Cécile Chougnet

http://www.w3.org/2001/XMLSchema#string

Eric Baudin

http://www.w3.org/2001/XMLSchema#string

Marie-Hélène Massicotte

http://www.w3.org/2001/XMLSchema#string

Martin Schlumberger

http://www.w3.org/2001/XMLSchema#string

Sophie Leboulleux

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

New therapeutic approaches to treat medullary thyroid carcinoma.

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

P304

125-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.6061/CLINICS/2012(SUP01)21

http://www.w3.org/2001/XMLSchema#string

P478

67 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22584717

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

Medullary carcinoma

thyroid cancer

P932

3328820

http://www.w3.org/2001/XMLSchema#string